In this expert discussion, Dr. VK Gadi and Dr. Ruta Rao break down the data that’s reshaping treatment for HER2-positive breast cancer — from DESTINY-Breast 05 and 11 to the first-line metastatic implications of DESTINY-Breast 09.

They explore what the numbers really mean for patients with residual disease, how CNS risk and toxicity factor into decision-making, and where T-DXd may (or may not) replace existing standards of care.

A candid, data-driven conversation for clinicians navigating HER2+ treatment today — and preparing for what comes next.

#HER2Positive #BreastCancer #TDXd #Oncology #CancerResearch #ESMO #ASCO #MedicalOncology #PrecisionMedicine #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded live, this in-depth conversation features Dr. Irene Kang and Dr. Aditya Bardia breaking down the DESTINY-Breast09 data and what it means for first-line treatment of metastatic HER2-positive breast cancer.

From challenging the long-standing THP standard to unpacking unprecedented progression-free survival, higher complete response rates, and CNS activity with T-DXd, this discussion explores how and why first-line decision-making is evolving. The panel also dives into patient selection, toxicity management, ILD monitoring, dose optimization, induction vs maintenance strategies, and how to frame these advances in real-world patient conversations.

A must-watch for clinicians navigating the next era of HER2-positive metastatic breast cancer care.

#HER2Positive #BreastCancer #DESTINYBreast09 #TDXd #Oncology #MedicalOncology #BreastOncology #CancerResearch #ClinicalTrials #PrecisionOncology #ESMO #ASCO #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded with Drs. Neil Iyengar and Komal Jhaveri, this in-depth discussion breaks down the most practice-shifting data in early-stage HER2-positive breast cancer — from neoadjuvant to adjuvant decision-making.

The conversation explores DESTINY-Breast11 and its unprecedented pathologic complete response rates with sequential T-DXd followed by THP, including an 83% pCR in hormone receptor–negative disease. The panel also examines safety, ILD risk, anthracycline-free strategies, and how these results may reshape neoadjuvant standards.

The discussion then moves to DESTINY-Breast05, where T-DXd demonstrated superiority over T-DM1 in the residual disease setting, with a hazard ratio of 0.5 for invasive disease-free survival — raising critical questions about patient selection, CNS recurrence, and curative intent strategies.

A must-watch episode for clinicians navigating the rapidly evolving HER2-positive landscape.

#BreastCancer #HER2Positive #EarlyStageBreastCancer #Oncology #MedicalOncology #DESTINYBreast11 #DESTINYBreast05 #TDXd #AntibodyDrugConjugates #NeoadjuvantTherapy #AdjuvantTherapy #CancerResearch #ClinicalTrials #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded live with Drs. Gregory Vidal and Nusayba Bagegni, this in-depth conversation tackles one of the most provocative questions in HER2-positive metastatic breast cancer today: are we finally approaching cure?

The discussion spans more than a decade of progress — from the CLEOPATRA regimen and its long tail of durable responders to the practice-changing data from DESTINY-Breast09 showing a 40-month progression-free survival with T-DXd plus pertuzumab.

The panel explores how Patina, HER2CLIMB-05, endocrine therapy integration, CNS disease, and patient-specific risk factors are reshaping first-line decision-making. With more options than ever before, this episode highlights why precision, sequencing, and shared decision-making now define HER2-positive care.

#BreastCancer #HER2Positive #MetastaticBreastCancer #Oncology #MedicalOncology #DESTINYBreast09 #PatinaTrial #HER2CLIMB #TDXd #AntibodyDrugConjugates #PrecisionOncology #CancerResearch #ClinicalTrials #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded live, this in-depth conversation features Dr. Alison Conlin and Dr. Heather McArthur as they break down the evolving role of antibody–drug conjugates in early-stage HER2-positive breast cancer.

The discussion dives into DESTINY-Breast 11 and DESTINY-Breast 05, exploring how trastuzumab deruxtecan is challenging long-standing neoadjuvant and adjuvant paradigms. From pathologic complete response and invasive disease-free survival to toxicity management, ILD monitoring, and patient selection, this episode tackles how clinicians are balancing escalation and de-escalation in curative-intent care.

A thoughtful, practical conversation on where HER2-positive treatment is headed — and how today’s decisions may redefine cure for high-risk patients.

#BreastCancer #HER2Positive #Oncology #EarlyBreastCancer #DB11 #DB05 #AntibodyDrugConjugates #TrastuzumabDeruxtecan #NeoadjuvantTherapy #AdjuvantTherapy #ClinicalTrials #PrecisionOncology #MedicalOncology

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

For more than a decade, the Cleopatra regimen transformed outcomes in HER2-positive metastatic breast cancer — delivering landmark overall survival gains and redefining long-term disease control.

Recorded at SABCS, this expert roundtable features Dr. Bill Gradishar, Dr. Tarah Ballinger, and Dr. Megan Kruse as they examine how the HER2 landscape is evolving in the era of antibody–drug conjugates.

The discussion explores the real-world impact of DESTINY-Breast09, the role of trastuzumab deruxtecan (T-DXd) in the first-line setting, and how clinicians are balancing efficacy, toxicity, and quality of life. From induction vs maintenance strategies to emerging data from PATINA and HER2CLIMB-05, this conversation highlights the nuance required in modern HER2+ decision-making.

🎧 A must-watch conversation on progress, uncertainty, and shared decision-making in HER2-positive metastatic breast cancer.

#HER2Positive #MetastaticBreastCancer #BreastCancer #Oncology #DESTINYBreast09 #TDXd #CleopatraTrial #AntibodyDrugConjugates #MedicalOncology #BreastOncology #SABCS #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

Recorded live around the latest data from SABCS, ASCO, and ESMO, this in-depth conversation features Dr. Mark Pegram and Dr. Carol Tweed examining whether the long-standing Cleopatra regimen is finally giving way to a new first-line standard in HER2-positive metastatic breast cancer.

From Destiny-Breast09 and unprecedented progression-free survival results to response depth, CNS considerations, and the real-world implications of continuous ADC therapy, this discussion breaks down what the data truly mean for patient care.

The conversation also explores induction vs. maintenance strategies, the role of endocrine therapy and CDK4/6 inhibitors, quality-of-life tradeoffs, pneumonitis risk, and how clinicians are navigating shared decision-making in an era of rapidly evolving options.

A must-watch episode for oncologists preparing for what may be the biggest first-line shift in HER2-positive metastatic disease in over a decade.

#BreastCancer #HER2Positive #MetastaticBreastCancer #Oncology #DestinyBreast09 #TrastuzumabDeruxtecan #ADCs #CleopatraRegimen #BreastOncology #CancerResearch #ClinicalTrials #MedicalOncology #PrecisionOncology #CommunityHealthMedia

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media

For more than a decade, CLEOPATRA defined first-line therapy in HER2-positive metastatic breast cancer.

Now, DESTINY-Breast09 is forcing a fundamental rethink.

In this in-depth roundtable, Drs. Neil Iyengar, Komal Jhaveri, and Igor Makhlin examine:

• The legacy — and limitations — of CLEOPATRA

• DESTINY-Breast09’s unprecedented ~40-month PFS

• When T-DXd + pertuzumab should move to the frontline

• Patient selection, toxicity management, and ILD vigilance

• Sequencing strategies after frontline ADCs

• How maintenance paradigms may evolve

A must-watch discussion on efficacy vs durability, escalation vs personalization, and what “best therapy first” truly means in 2025.

#HER2Positive #BreastCancer #Oncology #DESTINYBreast09 #TDXd #AntibodyDrugConjugates #CLEOPATRA #MetastaticBreastCancer #MedicalOncology #PrecisionOncology #ASCO #ESMO

–

Thanks for watching!

Our podcasts are also available on:

• Spotify - https://spotf.fi/chm-podcast

• Amazon Music - https://amazn.so/chm-podcast

• Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248

• Castbox - https://castbox.fm/vh/6735434

• Goodpods - https://goodpods.com/profile/chm-111066

• iHeartRadio - https://iheart.com/podcast/291542082

• Pocket Casts - https://pca.st/3ncdh11o

–

Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.

We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.

We specialize in:

• Peer to peer interviews, panels & round-tables

• Curated live events & conferences

• Professional in-depth content & research updates

• Interactive learning modules & webinars

• Live & on-demand webcasts & podcasts

Learn more about us here - https://communityhealth.media